Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
VINAY MENON's journey from Kerala in southern India to the heart of Chelsea Football Club is a remarkable story of transformation and influence.
Menon, who initially knew little about football, found himself at the forefront of one of the Premier League’s most successful teams, thanks to a chance encounter that would not only change his life but also leave a lasting impact on Chelsea.
In 2009, Menon, a wellness expert inspired by his yogi grandfather, was providing wellness services at a luxury hotel in Dubai. It was there that he was introduced to Roman Abramovich, the Russian billionaire and then-owner of Chelsea, through Abramovich’s father-in-law.
Impressed by Menon’s approach, Abramovich invited him to London to work privately with his family. This initial connection soon evolved into something much larger when Abramovich decided to integrate Menon’s wellness philosophy into his football club.
"Roman asked for it to happen and it happened. I was an Indian, who was never exposed to football, entering a massive club and it seemed impossible," Menon told the BBC.
"There was a big barrier, but it was not an immovable rock because it came from the owner himself - he initiated that change so everyone was ready to try."
Menon’s introduction to Chelsea’s Cobham training ground marked the beginning of a chapter in both his career and the club’s history. As the Premier League’s first wellness coach, Menon brought a fresh perspective to the team, focusing on mental well-being, meditation, and emotional balance.
His methods, though unconventional in the high-stakes world of football, gradually found acceptance among the players. Didier Drogba, one of Chelsea’s star strikers, was among the first to embrace Menon’s techniques, which led to a broader acceptance within the squad.
"Didier was the initial one – Chelsea is like one big family and we just sat and ate in the canteen with the players and so we started a conversation organically while eating. He asked what I can do for him, and I told him we can try this, and he asked me to try right away. That was the moment where football opened in front of me," Menon described the experience.
"After that Joe Cole, Frank Lampard, John Terry began coming to me to try it. The medical department were fantastic and made me part of their team, despite being from a different discipline."
Over the next 13 years, Menon became a fixture at Chelsea, working under multiple managers and contributing to the club’s numerous triumphs, including their Champions League victory in 2021.
His role was not limited to physical fitness but extended to nurturing the players’ mental resilience, a crucial aspect of performing at the highest level in professional sports.
Menon’s influence wasn’t just confined to Chelsea. In 2022, he took his expertise to the international stage, joining Roberto Martinez’s staff for the Belgium national team at the World Cup.
This move not only expanded his horizons but also brought attention to his home country, India, where football has yet to reach its full potential. Menon sees his journey as a beacon for aspiring young Indians, demonstrating that there is a place for them in the global football arena, even if not on the pitch.
Menon thinks that for his home country to make a mark on the international football stage, both the infrastructure and the prevailing mindset must undergo significant changes.
"We are a country of 1.4bn people and the main problem is filtration. We need a minimum 100 grassroots level clubs to filter this. It is about structuring the grassroots level and schools. If you systemise it, we will have a team," he was quoted as saying.
“At the last World Cup, many Indians were in Qatar and followed Messi and Ronaldo's journey. But we need a cultural change. Sports are important for the future, mental wellness, health, economy as well. I have had these conversations before in India and if my country needs me, I will always be there. I am sure sooner or later we will be at the World Cup."
Despite the changes at Chelsea following Abramovich’s departure in 2022, Menon remains optimistic about the club’s future under new ownership.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.